PVR and liver cancer: designed a nanoparticle that blocked the binding of TIGIT and CD155 and targeted LncRNA ANRIL, which exhibited a significant anti-tumor effect and increased the proportion of NK cells and T cells in an in vivo model of liver cancer (80).